Botulism Antitoxin Heptavalent (Equine) Types A, B, C, D, E, F, & G

Date: November 30, 2016

Please consult the Product Monograph\(^1\) for further information about this product.

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Cangene Corporation</th>
</tr>
</thead>
</table>

**Authorization and access**

Special authorization and access procedures must be followed:

**Botulism Antitoxin** Heptavalent - types A, B, C, D, E, F, & G

- The Office of the Chief Medical Officer of Health (OCMOH) must be notified by the fastest means possible of all cases for which botulism antitoxin is required
- Available on a 24-hour basis from Alberta Health by calling OCMOH pager: 780-638-3630. Special Access Program (SAP) forms and Manufacturer specific forms are included with the product. All forms must be completed and returned as outlined.

**Note:** This product is stocked in the Provincial Vaccine Depot

**Indications for use of botulism antitoxins (equine)**

**Treatment of botulism** – suspected or confirmed (administer immediately on suspicion of botulism - do not delay treatment waiting for lengthy clinical observations or confirmatory lab results)\(^1\)

**Notes:**

- Baby BIG\(^\circledR\) (Baby Botulism Immune Globulin) is the first-line therapy for naturally occurring infant botulism.\(^2\) See Baby BIG\(^\circledR\).
- Botulism Antitoxin (BAT) Heptavalent is not generally recommended for infants younger than one year of age.\(^2\)
- Botulism Antitoxin Heptavalent may be considered for non-type A & B infant botulism, on a case-by-case basis.\(^2\)

For further information about the disease and reporting requirements refer to Public Health Notifiable Disease Management Guidelines – Botulism.\(^3\)

**Dose**

Dose depends on age and weight. Refer to Product Monograph\(^1\).

**Note:** This is a treatment product administered under the direction of a physician in an acute care setting.

**Route**

Slow IV infusion. Refer to Product Monograph \(^1\).

**Schedule**

Treatment: Infusion depends on age and weight. Refer to Product Monograph \(^1\).

**Contraindications**

None

**Precautions**

Before administering Botulism-Antitoxin Heptavalent, the patient’s history should be carefully reviewed in order to determine whether the patient is at risk of an allergic reaction to equine protein (i.e., history of previous allergic reaction to equine protein, history of repeated use of antitoxin products). Refer to the current Product Monograph.

**Pregnancy**

There are no human or animal data to establish the presence or absence of risk associated with heptavalent BAT.\(^1\) Trivalent (A,B and E) BAT has been given to pregnant women without causing harm to mother or fetus. The benefit to the mother and the fetus from receiving heptavalent BAT for botulism should be weighed against the risk of harm from the treatment; decisions should be made on a case-by-case basis.
Lactation

There are no data to assess the presence or absence of heptavalent BAT in human milk, the effects on the breastfed child, or the effects on milk production. Botulism Antitoxin Heptavalent may considered on a case by case basis.

References

